Phase 3 VERITAC-2 trial results are in!

Vepdegestrant (ARV-471) significantly improved progression-free survival in ESR1-mutant ER+/HER2- metastatic breast cancer.
A major win for PROTAC in oncology! Regulatory filings & full data presentation coming soon.

Release: https://ir.arvinas.com/news-releases/news-release-details/arvinas-and-pfizer-announce-positive-topline-results-phase-3